Post-marketing surveillance: why medical device safety doesn’t end with certification

10.12.2025

Quality management // № 12, December 2025

Market leaders have long viewed post-marketing surveillance not as a costly obligation, but as an investment in their own future. There are examples in the history of medical technology when critical flaws were later discovered in the latest developments that received certification. Mass product recalls, lawsuits, destroyed consumer trust – all this cost companies much more than the development of a timely and transparent monitoring system.

The text of the article is available only in Ukrainian

Other news

11.06.2025

Practical guide for the use of European Medical Device Nomenclature

Read more
03.10.2023

Requirements, implementation and certification of HACCP / ISO 22000 in the production of dietary supplements

Read more
08.07.2025

Regulations in action: how the rules for aerosol sprayers have changed

Read more